3rd TGF-β for Immuno-Oncology Drug Development Summit

Exploit Understanding of TGF-β Biology, Harness Clinically Validated Biomarkers & Advance Safe & Efficacious Clinical Programs for Maximal Therapeutics Benefit in Immuno-Oncology.

In the past year alone, the field has learnt valuable lessons from the clinical trials and from the wider TGF-β field that will equip the immuno-oncology field with the knowledge needed to supercharge future TGF-β monotherapy or combinational therapeutics for precision medicine.

From uncovering the effects and production of TGF-β in immune, tumor and stromal cells to exploring predictive and pharmacodynamic TGF-β biomarkers for patient identification and assessing the clinical challenges that led to recent clinical failures, the 3rd TGF-β for Immuno-Oncology Drug Development Summit is your one-stop-shop dedicated to harnessing you with the knowledge to unlock the potential of successfully targeting TGF-β.

Tailored with 18+ senior leaders, the 2023 meeting will be taking place in-person for the first time – don’t miss your chance to be in the room for your comprehensive guide on TGF-β in immuno-oncology!

Whether you are new to this field or a seasoned expert, this meeting will provide you with the must-know takeaways from the basic biology to biomarkers to clinical trial design to overcome the clinical setbacks and produce a blockbuster TGF-β therapeutic.

To know more visit: https://ter.li/cjnpgy